董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rajesh Parekh | 男 | Director | 60 | 未披露 | 未持股 | 2021-05-19 |
| Ran Nussbaum | 男 | Director | 48 | 10.21万美元 | 未持股 | 2021-05-19 |
| Gadi Veinrib | 男 | Director | 42 | 9.21万美元 | 未持股 | 2021-05-19 |
| Zafrira Avnur | 女 | Director | 70 | 10.21万美元 | 未持股 | 2021-05-19 |
| Jasbir Seehra | 男 | Director | 65 | 9.96万美元 | 未持股 | 2021-05-19 |
| Sumit Aggarwal | 男 | Director, President and Chief Executive Officer | 49 | 未披露 | 未持股 | 2021-05-19 |
| Alan Walts | 男 | Director | 61 | 未披露 | 未持股 | 2021-05-19 |
| Gary D. Rakers | 男 | Executive Director, Finance and Accounting, Corporate Controller and Treasurer (Principal Financial and Principal Accounting Officer) | 37 | 未披露 | 未持股 | 2021-05-19 |
| Steven D. Rubin | 男 | Director | 60 | 10.21万美元 | 未持股 | 2021-05-19 |
| Tomer Kariv | 男 | Chairman of the Board | 60 | 9.21万美元 | 未持股 | 2021-05-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel Geffken | 男 | Interim Chief Financial Officer | 64 | 未披露 | 未持股 | 2021-05-19 |
| Sumit Aggarwal | 男 | Director, President and Chief Executive Officer | 49 | 未披露 | 未持股 | 2021-05-19 |
| Neil S. Belloff | 男 | Chief Operating Officer, General Counsel and Corporate Secretary | 61 | 143.49万美元 | 未持股 | 2021-05-19 |
| Vijay Modur | 男 | Head of Research and Development | 54 | 未披露 | 未持股 | 2021-05-19 |
| Gary D. Rakers | 男 | Executive Director, Finance and Accounting, Corporate Controller and Treasurer (Principal Financial and Principal Accounting Officer) | 37 | 未披露 | 未持股 | 2021-05-19 |
董事简历
中英对照 | 中文 | 英文- Rajesh Parekh
-
Rajesh Parekh自2004年以来担任Eloxx Pharmaceuticals, Inc.的董事会主席。他是Advent Life Sciences LLP（他于2005年加入）的普通合伙人。在牛津大学（Oxford University）的学术生涯中，他联合创立Oxford GlycoSciences PLC，在那里他担任首席科学官和首席执行官（从1988年到2003年它出售给Celltech Group PLC（现为UCB SA））。他创立或服务于美国和欧洲的一些生命科学公司的董事会，包括Celldex Therapeutics, Inc.； Avila Therapeutics, Inc.； EUSA Pharma （Europe） Limited； Thiakis Limited和Amsterdam Molecular Therapeutics （AMT） Holding N.V。（现为uniQure）。他目前担任Cellnovo Limited, PE Limited, F2G Limited, LuxFold S.A., Biocartis NV和Levicept Limited的董事会成员。他也是the Novartis Venture Fund的监事会（Supervisory Board）成员。他获得牛津大学（the University of Oxford）的生物化学硕士学位和分子医学哲学博士学位，在那里他也是高级研究员和教授。
Rajesh Parekh joined Eloxx Pharmaceuticals, Inc. Board on April 1 2021 and previously served as a director of Zikani Therapeutics, Inc. Dr. Parekh is a General Partner at Advent Life Sciences LLP, which he joined in 2006. During an academic career at Oxford University, he co-founded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC now UCB SA in 2003. He has founded or served on the boards of several life sciences companies in the United States and Europe including Avila Therapeutics, Inc., EUSA Pharma (Europe) Limited, Biocartis NV, Amsterdam Molecular Therapeutics (AMT) Holding NV (now uniQure), Aura, Inc., Itara Ltd., Cellnovo SA, Artax, Inc., and Project Paradise Limited. He was also a member of the Supervisory Board of the Novartis Venture Fund and is currently Chairman of the Board of Directors of Galapagos nv, (a public biotech company). Dr. Parekh also currently serves as a member of the board of directors of Advent Venture Partners LLP, Advent Life Sciences LLP, Aleta, Inc., Alpha Anomeric SA, Amphista Therapeutics Ltd., Arrakis, Inc., Aura Biosciences, Capella BioSciences Ltd., Levicept Limited, PE Limited, Pheno Therapeutics Ltd., and Tridek-One Therapeutics SAS. Mr. Parekh also served as a director of Zikani prior to its acquisition by the Company. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he has also been a Senior Research Fellow and Professor. - Rajesh Parekh自2004年以来担任Eloxx Pharmaceuticals, Inc.的董事会主席。他是Advent Life Sciences LLP（他于2005年加入）的普通合伙人。在牛津大学（Oxford University）的学术生涯中，他联合创立Oxford GlycoSciences PLC，在那里他担任首席科学官和首席执行官（从1988年到2003年它出售给Celltech Group PLC（现为UCB SA））。他创立或服务于美国和欧洲的一些生命科学公司的董事会，包括Celldex Therapeutics, Inc.； Avila Therapeutics, Inc.； EUSA Pharma （Europe） Limited； Thiakis Limited和Amsterdam Molecular Therapeutics （AMT） Holding N.V。（现为uniQure）。他目前担任Cellnovo Limited, PE Limited, F2G Limited, LuxFold S.A., Biocartis NV和Levicept Limited的董事会成员。他也是the Novartis Venture Fund的监事会（Supervisory Board）成员。他获得牛津大学（the University of Oxford）的生物化学硕士学位和分子医学哲学博士学位，在那里他也是高级研究员和教授。
- Rajesh Parekh joined Eloxx Pharmaceuticals, Inc. Board on April 1 2021 and previously served as a director of Zikani Therapeutics, Inc. Dr. Parekh is a General Partner at Advent Life Sciences LLP, which he joined in 2006. During an academic career at Oxford University, he co-founded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC now UCB SA in 2003. He has founded or served on the boards of several life sciences companies in the United States and Europe including Avila Therapeutics, Inc., EUSA Pharma (Europe) Limited, Biocartis NV, Amsterdam Molecular Therapeutics (AMT) Holding NV (now uniQure), Aura, Inc., Itara Ltd., Cellnovo SA, Artax, Inc., and Project Paradise Limited. He was also a member of the Supervisory Board of the Novartis Venture Fund and is currently Chairman of the Board of Directors of Galapagos nv, (a public biotech company). Dr. Parekh also currently serves as a member of the board of directors of Advent Venture Partners LLP, Advent Life Sciences LLP, Aleta, Inc., Alpha Anomeric SA, Amphista Therapeutics Ltd., Arrakis, Inc., Aura Biosciences, Capella BioSciences Ltd., Levicept Limited, PE Limited, Pheno Therapeutics Ltd., and Tridek-One Therapeutics SAS. Mr. Parekh also served as a director of Zikani prior to its acquisition by the Company. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he has also been a Senior Research Fellow and Professor.
- Ran Nussbaum
-
Ran Nussbaum自2013年7月1日起担任董事。Nussbaum是 Pontifax Group（一家风险资本公司）联合创始人，自2004年起担任管理合伙人。Nussbaum现任多个公司董事，包括：Kite Pharma Inc. NASDAQ：KITE （自2013年7月起担任）；Eloxx Pharmaceuticals, Ltd. （自2013年9月起担任）， UroGen Pharma Ltd. （自2013年4月起担任）， Quiet Therapeutics Ltd. （自2010年9月起担任）， Ocon Medical Ltd. （自2013年5月起担任）， Nutrina Ltd. （自2014年12月起担任）， N.T.B Pharma Ltd. （自2015年11月起担任） and NovellusDx Ltd. （自2015年12月起担任）。此外，Nussbaum之前曾担任多个董事，包括CollPlant Holdings Ltd. （TASE：CLPT） （2010年5月到2014年8月）， Protab Ltd. （2010年12月到2014年8月）， Fusimab Ltd. （2010年7月到2014年12月）， c-Cam Biotherapeutics Ltd. （2012年4月到2015年7月） and Insuline Medical Ltd. （TASE：INSL） （2013年12月到2015年1月）。
Ran Nussbaum has served as a member of our Board since December 2017 and previously served as a member of the Eloxx Limited Board since September 2013. Mr. Nussbaum is a managing partner and Co-Founder of The Pontifax Group, which established seven funds with over $1 billion under management and invested in over 100 portfolio companies. Over the past 15 years, Mr. Nussbaum has been managing The Pontifax Group's activity together with Mr. Tomer Kariv. Mr. Nussbaum is the Chairman of the Board of Keros Therapeutics Inc. a public biotech company where Mr. Nussbaum also serves as chair of the compensation committee. He currently serves as a Director of UroGen Pharma, Inc. (a public biotech company where he also serves as a member of the compensation, nominating and corporate governance committee), and Lutris Pharma Ltd.Mr. Nussbaum also previously served on the boards of directors of many of The Pontifax Group's portfolio companies: Quiet Therapeutics Ltd., Ocon Medical Ltd., N.T.B. Pharma Ltd., ArQule, Inc. (acquired by Merck in January 2020), Zolex Therapeutics Ltd., c-Cam Biotherapeutics Ltd. (acquired by Merck), Kite Pharma, Inc., BioBlast Pharma Ltd., Nutrinia Ltd., Biomedix Ltd., Nasvax Ltd., NovellusDx Ltd., VBI Vaccines Inc. and Prevail Therapeutics, Inc. (acquired by Eli Lilly and Company in January 2021). - Ran Nussbaum自2013年7月1日起担任董事。Nussbaum是 Pontifax Group（一家风险资本公司）联合创始人，自2004年起担任管理合伙人。Nussbaum现任多个公司董事，包括：Kite Pharma Inc. NASDAQ：KITE （自2013年7月起担任）；Eloxx Pharmaceuticals, Ltd. （自2013年9月起担任）， UroGen Pharma Ltd. （自2013年4月起担任）， Quiet Therapeutics Ltd. （自2010年9月起担任）， Ocon Medical Ltd. （自2013年5月起担任）， Nutrina Ltd. （自2014年12月起担任）， N.T.B Pharma Ltd. （自2015年11月起担任） and NovellusDx Ltd. （自2015年12月起担任）。此外，Nussbaum之前曾担任多个董事，包括CollPlant Holdings Ltd. （TASE：CLPT） （2010年5月到2014年8月）， Protab Ltd. （2010年12月到2014年8月）， Fusimab Ltd. （2010年7月到2014年12月）， c-Cam Biotherapeutics Ltd. （2012年4月到2015年7月） and Insuline Medical Ltd. （TASE：INSL） （2013年12月到2015年1月）。
- Ran Nussbaum has served as a member of our Board since December 2017 and previously served as a member of the Eloxx Limited Board since September 2013. Mr. Nussbaum is a managing partner and Co-Founder of The Pontifax Group, which established seven funds with over $1 billion under management and invested in over 100 portfolio companies. Over the past 15 years, Mr. Nussbaum has been managing The Pontifax Group's activity together with Mr. Tomer Kariv. Mr. Nussbaum is the Chairman of the Board of Keros Therapeutics Inc. a public biotech company where Mr. Nussbaum also serves as chair of the compensation committee. He currently serves as a Director of UroGen Pharma, Inc. (a public biotech company where he also serves as a member of the compensation, nominating and corporate governance committee), and Lutris Pharma Ltd.Mr. Nussbaum also previously served on the boards of directors of many of The Pontifax Group's portfolio companies: Quiet Therapeutics Ltd., Ocon Medical Ltd., N.T.B. Pharma Ltd., ArQule, Inc. (acquired by Merck in January 2020), Zolex Therapeutics Ltd., c-Cam Biotherapeutics Ltd. (acquired by Merck), Kite Pharma, Inc., BioBlast Pharma Ltd., Nutrinia Ltd., Biomedix Ltd., Nasvax Ltd., NovellusDx Ltd., VBI Vaccines Inc. and Prevail Therapeutics, Inc. (acquired by Eli Lilly and Company in January 2021).
- Gadi Veinrib
-
Gadi Veinrib自2017年12月起担任董事会成员，此前自2014年11月起担任Eloxx Limited董事会成员。他是A-Grade Investments的合伙人。Veinrib先生于2011年至2013年7月担任Elron Electronic Industries Ltd.的Vice President。在Elron之前，Veinrib先生在Discount Investment Corporation DIC任职，担任DIC的总裁助理兼首席执行官。Veinrib先生在特拉维夫大学（Tel Aviv University）获得经济学学士学位。
Gadi Veinrib has served as a member of our Board since 2017. Mr. Veinrib previously served as a member of the Eloxx Limited Board since November 2014. Mr. Veinrib serves as the Chairman of the Board of Aqua Maof Aquaculture Technologies Ltd., a world leader in indoor aquaculture technology, as well as other companies in the Aqua Maof Global Aquaculture Group. Mr. Veinrib serves as a board member in Israeli based Meteo-Logic Ltd., SGCI and Minute Ltd. Mr. Veinrib served as Vice President of Elron Electronic Industries Ltd., as well as a director of companies within Discount Investment Corporation Ltd. a member of the IDB Group, including Netvision Ltd., RDSeed Ltd., Cloudyn Software Ltd. and Nana10 Ltd. Mr. Veinrib holds a B.A. in Economics from Tel Aviv University. - Gadi Veinrib自2017年12月起担任董事会成员，此前自2014年11月起担任Eloxx Limited董事会成员。他是A-Grade Investments的合伙人。Veinrib先生于2011年至2013年7月担任Elron Electronic Industries Ltd.的Vice President。在Elron之前，Veinrib先生在Discount Investment Corporation DIC任职，担任DIC的总裁助理兼首席执行官。Veinrib先生在特拉维夫大学（Tel Aviv University）获得经济学学士学位。
- Gadi Veinrib has served as a member of our Board since 2017. Mr. Veinrib previously served as a member of the Eloxx Limited Board since November 2014. Mr. Veinrib serves as the Chairman of the Board of Aqua Maof Aquaculture Technologies Ltd., a world leader in indoor aquaculture technology, as well as other companies in the Aqua Maof Global Aquaculture Group. Mr. Veinrib serves as a board member in Israeli based Meteo-Logic Ltd., SGCI and Minute Ltd. Mr. Veinrib served as Vice President of Elron Electronic Industries Ltd., as well as a director of companies within Discount Investment Corporation Ltd. a member of the IDB Group, including Netvision Ltd., RDSeed Ltd., Cloudyn Software Ltd. and Nana10 Ltd. Mr. Veinrib holds a B.A. in Economics from Tel Aviv University.
- Zafrira Avnur
-
Zafrira Avnur自2017年12月起担任董事会成员，此前自2017年6月起担任Eloxx Limited董事会成员。Avnur博士是Quark Venture Inc.的首席科学官，该公司是一家专注于生命科学投资的风险投资基金。在加入Quark之前，Avnur博士于2009年至2016年10月担任Roche Partnering学术创新全球主管。Avnur博士从2010年到2012年还被任命为Roche Partnering被忽视疾病的全球主管。她还创建了9家创业公司。在担任学术创新领导职务之前，Avnur博士负责合作机会的科学评估，并在罗氏公司（Roche）成立了所有治疗领域生物标志物发现者小组。她担任制药和诊断部门之间的联络人，并为PHC个性化医疗保健计划做出贡献。在担任合伙人之前，Avnur博士研究与开发的诊断和制药行业工作了近20年。她曾担任一些职务，从科学家和经理发展到全球责任。在这个职位上，她监督化合物从板凳到临床的进展，并参与了早期临床研究的设计和执行，这些研究表征了许多化合物的药效学和临床效果。Avnur博士获得了理学学士学位。生物学和理学硕士学位。Ben Gurion University生物学博士学位和Wizmann Institute免疫学博士学位。
Zafrira Avnur has served as a member of our Board since December 2017 and previously served as a member of the Eloxx Limited Board since June 2017. Dr. Avnur is the Chief Scientific Officer at Quark Venture Inc., a venture investment fund focused on life sciences investments. Prior to Quark, Dr. Avnur was the Global Head of Academic Innovation, Roche Partnering from 2009 until October 2016. Dr. Avnur was also named Global Head of Neglected Diseases Roche Partnering from 2010 until 2012. She also has created nine startup companies and serves on the board of directors of several portfolio companies. Preceding her academic innovation leadership role, Dr. Avnur assumed responsibility for scientific evaluations of partnering opportunities and started the “Finder” group for Biomarkers for all therapeutic areas at Roche. She acted as Liaison between Pharma and Diagnostic Divisions and contributed to the PHC Personalized Health Care initiative. Prior to her partnering roles, Dr. Avnur worked in diagnostics and pharmaceuticals research and development for nearly 20 years. She held a number of positions progressing from scientist and manager to global responsibilities. In these roles she was overseeing the advancement of compounds from the bench into the clinic, and was involved in the design and execution of early clinical studies that characterize the pharmacodynamics and clinical effects of a number of compounds. Dr. Avnur received a B.Sc. in Biology and a M.Sc. in Biology from Ben Gurion University and a Ph.D. in Immunology from the Weizmann Institute of Science. Dr. Avnur also conducted post-doctoral work at Stanford Medical Center in the Cancer Immunology Department. - Zafrira Avnur自2017年12月起担任董事会成员，此前自2017年6月起担任Eloxx Limited董事会成员。Avnur博士是Quark Venture Inc.的首席科学官，该公司是一家专注于生命科学投资的风险投资基金。在加入Quark之前，Avnur博士于2009年至2016年10月担任Roche Partnering学术创新全球主管。Avnur博士从2010年到2012年还被任命为Roche Partnering被忽视疾病的全球主管。她还创建了9家创业公司。在担任学术创新领导职务之前，Avnur博士负责合作机会的科学评估，并在罗氏公司（Roche）成立了所有治疗领域生物标志物发现者小组。她担任制药和诊断部门之间的联络人，并为PHC个性化医疗保健计划做出贡献。在担任合伙人之前，Avnur博士研究与开发的诊断和制药行业工作了近20年。她曾担任一些职务，从科学家和经理发展到全球责任。在这个职位上，她监督化合物从板凳到临床的进展，并参与了早期临床研究的设计和执行，这些研究表征了许多化合物的药效学和临床效果。Avnur博士获得了理学学士学位。生物学和理学硕士学位。Ben Gurion University生物学博士学位和Wizmann Institute免疫学博士学位。
- Zafrira Avnur has served as a member of our Board since December 2017 and previously served as a member of the Eloxx Limited Board since June 2017. Dr. Avnur is the Chief Scientific Officer at Quark Venture Inc., a venture investment fund focused on life sciences investments. Prior to Quark, Dr. Avnur was the Global Head of Academic Innovation, Roche Partnering from 2009 until October 2016. Dr. Avnur was also named Global Head of Neglected Diseases Roche Partnering from 2010 until 2012. She also has created nine startup companies and serves on the board of directors of several portfolio companies. Preceding her academic innovation leadership role, Dr. Avnur assumed responsibility for scientific evaluations of partnering opportunities and started the “Finder” group for Biomarkers for all therapeutic areas at Roche. She acted as Liaison between Pharma and Diagnostic Divisions and contributed to the PHC Personalized Health Care initiative. Prior to her partnering roles, Dr. Avnur worked in diagnostics and pharmaceuticals research and development for nearly 20 years. She held a number of positions progressing from scientist and manager to global responsibilities. In these roles she was overseeing the advancement of compounds from the bench into the clinic, and was involved in the design and execution of early clinical studies that characterize the pharmacodynamics and clinical effects of a number of compounds. Dr. Avnur received a B.Sc. in Biology and a M.Sc. in Biology from Ben Gurion University and a Ph.D. in Immunology from the Weizmann Institute of Science. Dr. Avnur also conducted post-doctoral work at Stanford Medical Center in the Cancer Immunology Department.
- Jasbir Seehra
-
Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
Jasbir Seehra has served as a member of our Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology. - Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
- Jasbir Seehra has served as a member of our Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology.
- Sumit Aggarwal
-
Sumit Aggarwal于2021年4月1日加入Eloxx，担任我们的总裁兼首席执行官，自2019年以来一直担任Zikani的总裁兼首席执行官兼董事。Aggarwal先生于2018年加入Zikani，担任首席财务官兼首席商务官，并领导Zikani从一家早期技术公司转变为一家专注于罕见病和肿瘤学的组织。在加入Zikani之前，Aggarwal先生于2015年至2018年担任Progenity, Inc.的代理总裁兼首席财务官，该公司是一家私人基因服务公司，为OB/GYN实践提供产前基因测试。从2016年到2018年，Aggarwal先生担任Neoseq董事会成员，Neoseq是一家私营的基于基因测序的诊断公司。Aggarwal先生还在Adage Capital的医疗保健和生物技术领域担任领导职务，并在McKinsey&Company的医疗保健实践中担任副合伙人。Aggarwal先生在制药和生物技术商业运营，投资管理，管理咨询方面拥有超过20年的经验，并通过重新振兴创新，增长和盈利能力以及为有前途的技术公司筹集资金，成功地改造了公司。Aggarwal先生拥有康奈尔大学约翰逊学院的工商管理硕士学位，以及哈拉格布尔印度理工学院的化学工程学士学位。
Sumit Aggarwal joined Eloxx as our President and Chief Executive Officer on April 1 2021 and previously served as President and Chief Executive Officer and a director of Zikani since 2019. Mr. Aggarwal joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer, and led the transformation of Zikani from an early-stage technology company to a rare disease and oncology-focused organization. Prior to joining Zikani, from 2015 to 2018 Mr. Aggarwal served as acting President and Chief Financial Officer of Progenity, Inc., a private genetic services company offering pre-natal genetic testing to OB/GYN practices. From 2016 to 2018 Mr. Aggarwal served as a member of the board of directors of NEOSEQ, a privately-held genetic sequencing-based diagnostic company. Mr. Aggarwal has also held leadership roles in healthcare and biotechnology at Adage Capital and as an Associate Partner at McKinsey & Company in its healthcare practice. Mr. Aggarwal has more than 20 years of experience in pharmaceutical and biotechnology commercial operations, investment management, management consulting, and has been successful in transforming companies by re-invigorating innovation, growth and profitability, and raising capital for promising technology companies. Mr. Aggarwal holds an M.B.A. with distinction from the Johnson School, Cornell University, and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur. - Sumit Aggarwal于2021年4月1日加入Eloxx，担任我们的总裁兼首席执行官，自2019年以来一直担任Zikani的总裁兼首席执行官兼董事。Aggarwal先生于2018年加入Zikani，担任首席财务官兼首席商务官，并领导Zikani从一家早期技术公司转变为一家专注于罕见病和肿瘤学的组织。在加入Zikani之前，Aggarwal先生于2015年至2018年担任Progenity, Inc.的代理总裁兼首席财务官，该公司是一家私人基因服务公司，为OB/GYN实践提供产前基因测试。从2016年到2018年，Aggarwal先生担任Neoseq董事会成员，Neoseq是一家私营的基于基因测序的诊断公司。Aggarwal先生还在Adage Capital的医疗保健和生物技术领域担任领导职务，并在McKinsey&Company的医疗保健实践中担任副合伙人。Aggarwal先生在制药和生物技术商业运营，投资管理，管理咨询方面拥有超过20年的经验，并通过重新振兴创新，增长和盈利能力以及为有前途的技术公司筹集资金，成功地改造了公司。Aggarwal先生拥有康奈尔大学约翰逊学院的工商管理硕士学位，以及哈拉格布尔印度理工学院的化学工程学士学位。
- Sumit Aggarwal joined Eloxx as our President and Chief Executive Officer on April 1 2021 and previously served as President and Chief Executive Officer and a director of Zikani since 2019. Mr. Aggarwal joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer, and led the transformation of Zikani from an early-stage technology company to a rare disease and oncology-focused organization. Prior to joining Zikani, from 2015 to 2018 Mr. Aggarwal served as acting President and Chief Financial Officer of Progenity, Inc., a private genetic services company offering pre-natal genetic testing to OB/GYN practices. From 2016 to 2018 Mr. Aggarwal served as a member of the board of directors of NEOSEQ, a privately-held genetic sequencing-based diagnostic company. Mr. Aggarwal has also held leadership roles in healthcare and biotechnology at Adage Capital and as an Associate Partner at McKinsey & Company in its healthcare practice. Mr. Aggarwal has more than 20 years of experience in pharmaceutical and biotechnology commercial operations, investment management, management consulting, and has been successful in transforming companies by re-invigorating innovation, growth and profitability, and raising capital for promising technology companies. Mr. Aggarwal holds an M.B.A. with distinction from the Johnson School, Cornell University, and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur.
- Alan Walts
-
Alan Walts于2021年4月1日加入我们的董事会，此前自2020年5月起担任Zikani的执行主席。Walts博士是Advent Life Sciences的美国风险合伙人，自2014年1月起担任该职位。Walts博士自2016年以来担任PIC Therapeutics和Artax Biopharma的执行主席兼董事（自2017年以来）。沃尔茨博士还是特米尔基金会的创始人，董事兼财务主管，该基金会是一家成立于2019年的501（c）（3）公共组织。Walts博士目前是Neuroelectrics Corp的独立董事，以及几家私人公司的业务顾问和董事会观察员，包括Amylyx Pharmaceuticals，Arrakis Therapeutics，Alpha Anomeric和Amphista Therapeutics。Walts博士之前的董事会经验包括X4Pharmaceuticals（董事兼联合创始人，审计和提名/治理委员会成员，2013年至2019年），Aura Biosciences（执行主席，董事，审计委员会成员，2013年至2019年）和Arrakis Therapeutics（联合创始人，执行主席兼董事，2015年至2019年）。Walts博士在Genzyme拥有超过25年的行业经验，涉及业务开发、业务战略、研究与开发、综合管理和风险投资。在2013年离开Genzyme之前，Walts博士最近管理Genzyme的公司风险基金Genzyme Ventures（现为Sanofi Ventures）。1985年，Walts博士获得了麻省理工学院的化学博士学位，与Christopher Walsh教授一起在麻省理工学院进行了生物化学的博士后研究，并完成了哈佛商学院的管理发展执行项目。
Alan Walts joined our Board on April 1 2021 and previously served as Executive Chairman of Zikani since May 2020. Dr. Walts is a US-based Venture Partner with Advent Life Sciences, a position he has held since January 2014. Dr. Walts serves as Executive Chairman and Director of PIC Therapeutics since 2016 and Artax Biopharma (since 2017). Dr. Walts is also a founder, Director and Treasurer of The Termeer Foundation, a public 501(c)(3) organization founded in 2019. Dr. Walts is currently an independent Director of Neuroelectrics Corp, and a business advisor and board observer of several private companies including Amylyx Pharmaceuticals, Arrakis Therapeutics, Alpha Anomeric and Amphista Therapeutics. Dr. Walts' previous board experience includes X4 Pharmaceuticals (Director and co-founder, audit and nominating/governance committee member, 2013-2019), Aura Biosciences (Executive Chairman, Director, audit committee member, 2013-2019), and Arrakis Therapeutics (co-founder, Executive Chairman and Director, 2015-2019).Dr. Walts has over 25 years of industry experience at Genzyme in business development, business strategy, research and development, general management, and venture capital. Prior to leaving Genzyme in 2013 Dr. Walts most recently managed Genzyme's corporate venture fund, Genzyme Ventures (now Sanofi Ventures). Dr. Walts received a Ph.D. in chemistry from MIT in 1985 carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School. - Alan Walts于2021年4月1日加入我们的董事会，此前自2020年5月起担任Zikani的执行主席。Walts博士是Advent Life Sciences的美国风险合伙人，自2014年1月起担任该职位。Walts博士自2016年以来担任PIC Therapeutics和Artax Biopharma的执行主席兼董事（自2017年以来）。沃尔茨博士还是特米尔基金会的创始人，董事兼财务主管，该基金会是一家成立于2019年的501（c）（3）公共组织。Walts博士目前是Neuroelectrics Corp的独立董事，以及几家私人公司的业务顾问和董事会观察员，包括Amylyx Pharmaceuticals，Arrakis Therapeutics，Alpha Anomeric和Amphista Therapeutics。Walts博士之前的董事会经验包括X4Pharmaceuticals（董事兼联合创始人，审计和提名/治理委员会成员，2013年至2019年），Aura Biosciences（执行主席，董事，审计委员会成员，2013年至2019年）和Arrakis Therapeutics（联合创始人，执行主席兼董事，2015年至2019年）。Walts博士在Genzyme拥有超过25年的行业经验，涉及业务开发、业务战略、研究与开发、综合管理和风险投资。在2013年离开Genzyme之前，Walts博士最近管理Genzyme的公司风险基金Genzyme Ventures（现为Sanofi Ventures）。1985年，Walts博士获得了麻省理工学院的化学博士学位，与Christopher Walsh教授一起在麻省理工学院进行了生物化学的博士后研究，并完成了哈佛商学院的管理发展执行项目。
- Alan Walts joined our Board on April 1 2021 and previously served as Executive Chairman of Zikani since May 2020. Dr. Walts is a US-based Venture Partner with Advent Life Sciences, a position he has held since January 2014. Dr. Walts serves as Executive Chairman and Director of PIC Therapeutics since 2016 and Artax Biopharma (since 2017). Dr. Walts is also a founder, Director and Treasurer of The Termeer Foundation, a public 501(c)(3) organization founded in 2019. Dr. Walts is currently an independent Director of Neuroelectrics Corp, and a business advisor and board observer of several private companies including Amylyx Pharmaceuticals, Arrakis Therapeutics, Alpha Anomeric and Amphista Therapeutics. Dr. Walts' previous board experience includes X4 Pharmaceuticals (Director and co-founder, audit and nominating/governance committee member, 2013-2019), Aura Biosciences (Executive Chairman, Director, audit committee member, 2013-2019), and Arrakis Therapeutics (co-founder, Executive Chairman and Director, 2015-2019).Dr. Walts has over 25 years of industry experience at Genzyme in business development, business strategy, research and development, general management, and venture capital. Prior to leaving Genzyme in 2013 Dr. Walts most recently managed Genzyme's corporate venture fund, Genzyme Ventures (now Sanofi Ventures). Dr. Walts received a Ph.D. in chemistry from MIT in 1985 carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School.
- Gary D. Rakers
-
Gary D.Rakers于2020年1月加入Eloxx，此前曾担任我们的公司财务总监兼助理财务主管，并于2021年3月26日晋升为执行董事，财务和会计，公司财务总监兼财务主管。在这之前，Rakers先生在Tesaro, Inc.（一家专注于肿瘤的生物制药公司）工作了6年，最终担任技术会计和运营副总监。Tesaro于2019年被GlaxoSmithKline plc收购。在Totesaro之前，Rakers先生在Deloitte&Touche LLP的审计和保证实践工作了8年，专注于医疗保健和生命科学部门，包括医疗保健提供商，医疗保健保险公司和制药公司，从发现到商业化。Rakers先生是一名注册会计师，拥有本特利大学会计硕士学位。
Gary D. Rakers joined Eloxx in January 2020 previously served as our Corporate Controller and Assistant Treasurer and was promoted to Executive Director, Finance and Accounting, Corporate Controller and Treasurer on March 26 2021. Previously, Mr. Rakers spent 6 years with Tesaro, Inc., an oncology-focused biopharmaceutical company, culminating with the role of Associate Director of Technical Accounting and Operations. Tesaro was acquired by GlaxoSmithKline plc in 2019. Prior toTesaro, Mr. Rakers spent 8 years in the audit and assurance practice of Deloitte & Touche LLP, with a focus on the healthcare and life sciences sector, including healthcare providers, healthcare insurers and pharmaceutical companies from discovery through commercialization. Mr. Rakers, a certified public accountant, holds an M.S.A. in Accounting from Bentley University. - Gary D.Rakers于2020年1月加入Eloxx，此前曾担任我们的公司财务总监兼助理财务主管，并于2021年3月26日晋升为执行董事，财务和会计，公司财务总监兼财务主管。在这之前，Rakers先生在Tesaro, Inc.（一家专注于肿瘤的生物制药公司）工作了6年，最终担任技术会计和运营副总监。Tesaro于2019年被GlaxoSmithKline plc收购。在Totesaro之前，Rakers先生在Deloitte&Touche LLP的审计和保证实践工作了8年，专注于医疗保健和生命科学部门，包括医疗保健提供商，医疗保健保险公司和制药公司，从发现到商业化。Rakers先生是一名注册会计师，拥有本特利大学会计硕士学位。
- Gary D. Rakers joined Eloxx in January 2020 previously served as our Corporate Controller and Assistant Treasurer and was promoted to Executive Director, Finance and Accounting, Corporate Controller and Treasurer on March 26 2021. Previously, Mr. Rakers spent 6 years with Tesaro, Inc., an oncology-focused biopharmaceutical company, culminating with the role of Associate Director of Technical Accounting and Operations. Tesaro was acquired by GlaxoSmithKline plc in 2019. Prior toTesaro, Mr. Rakers spent 8 years in the audit and assurance practice of Deloitte & Touche LLP, with a focus on the healthcare and life sciences sector, including healthcare providers, healthcare insurers and pharmaceutical companies from discovery through commercialization. Mr. Rakers, a certified public accountant, holds an M.S.A. in Accounting from Bentley University.
- Steven D. Rubin
-
Steven D. Rubin，自企业于2009年10月合并，他担任董事会成员。他担任Ideation 的秘书从2007年6月至2009年10月。他一直是OPKO健康公司执行副总裁自2007年5月起，是OPKO健康公司的董事自2007年2月起，是冰霜集团有限责任公司（一家私人投资公司）的一员。他目前担任OPKO健康公司（一家专业的医疗保健公司），非侵入监测系统公司（一家医疗器械公司），Neovasc公司（血管器械开发商），Kidville公司（经营高档的儿童的学习和游乐设施），老虎X医药公司（前身为卡尔医药公司，前身是一家医疗器械公司），和城堡的品牌公司（高档白酒的营销商）的董事会成员。他曾担任梦公司（一家垂直整合的运动许可和产品的公司）， Ideation，TransEnterix公司（原SafeStitch医药公司）-一家医疗设备公司和PROLOR Biotech公司（一个发展阶段的生物制药公司）的董事会成员，在与OPKO健康公司合并之前。他曾任IVAX公司的高级副总裁，总法律顾问兼秘书从2001年8月至2006年9月。
Steven D. Rubin has served as a member of our Board since May 2014 when the Company was known as Sevion Therapeutics, Inc., until its merger with Eloxx Pharmaceuticals, Ltd. in December 2017. Mr. Rubin is the Executive Vice President - Administration and a Director of OPKO Health, Inc. Mr. Rubin is currently a Director of Red Violet, Inc. a public software and services company where he serves as a member of the audit committee and chair of both the compensation and nominating and corporate governance committees, Kidville, Inc., Non-Invasive Monitoring Systems, Inc., Cocrystal Pharma, Inc. (a public biotech company where he serves as the chair of both the audit and compensation committees and a member of the and nominating and corporate governance committee), Neovasc, Inc. and ChromaDex Corp. (a public bioscience company where he serves as the chair of the nominating and corporate governance committee). Mr. Rubin previously served as a Director of Cogint, Inc. prior to the spinoff of Red Violet from Cogint in March 2018 Dreams, Inc., Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc., SciVac Therapeutics, Inc. prior to its merger with VBI Vaccines, Inc., Castle Brands, Inc., Tiger X Medical, Inc. prior to its merger with BioCardia, Inc., and PROLOR Biotech, Inc. prior to its acquisition by OPKO Health, Inc. Mr. Rubin received a B.A. in Economics from Tulane University and a J.D. from the University of Florida. - Steven D. Rubin，自企业于2009年10月合并，他担任董事会成员。他担任Ideation 的秘书从2007年6月至2009年10月。他一直是OPKO健康公司执行副总裁自2007年5月起，是OPKO健康公司的董事自2007年2月起，是冰霜集团有限责任公司（一家私人投资公司）的一员。他目前担任OPKO健康公司（一家专业的医疗保健公司），非侵入监测系统公司（一家医疗器械公司），Neovasc公司（血管器械开发商），Kidville公司（经营高档的儿童的学习和游乐设施），老虎X医药公司（前身为卡尔医药公司，前身是一家医疗器械公司），和城堡的品牌公司（高档白酒的营销商）的董事会成员。他曾担任梦公司（一家垂直整合的运动许可和产品的公司）， Ideation，TransEnterix公司（原SafeStitch医药公司）-一家医疗设备公司和PROLOR Biotech公司（一个发展阶段的生物制药公司）的董事会成员，在与OPKO健康公司合并之前。他曾任IVAX公司的高级副总裁，总法律顾问兼秘书从2001年8月至2006年9月。
- Steven D. Rubin has served as a member of our Board since May 2014 when the Company was known as Sevion Therapeutics, Inc., until its merger with Eloxx Pharmaceuticals, Ltd. in December 2017. Mr. Rubin is the Executive Vice President - Administration and a Director of OPKO Health, Inc. Mr. Rubin is currently a Director of Red Violet, Inc. a public software and services company where he serves as a member of the audit committee and chair of both the compensation and nominating and corporate governance committees, Kidville, Inc., Non-Invasive Monitoring Systems, Inc., Cocrystal Pharma, Inc. (a public biotech company where he serves as the chair of both the audit and compensation committees and a member of the and nominating and corporate governance committee), Neovasc, Inc. and ChromaDex Corp. (a public bioscience company where he serves as the chair of the nominating and corporate governance committee). Mr. Rubin previously served as a Director of Cogint, Inc. prior to the spinoff of Red Violet from Cogint in March 2018 Dreams, Inc., Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc., SciVac Therapeutics, Inc. prior to its merger with VBI Vaccines, Inc., Castle Brands, Inc., Tiger X Medical, Inc. prior to its merger with BioCardia, Inc., and PROLOR Biotech, Inc. prior to its acquisition by OPKO Health, Inc. Mr. Rubin received a B.A. in Economics from Tulane University and a J.D. from the University of Florida.
- Tomer Kariv
-
Tomer Kariv，2008年3月加入本公司。他是Pontifax的共同创始人、首席执行官，这是以色列的生命科学行业投资基金集团，也是本公司的股东，专注于发展阶段的生物制药公司、医疗科技公司的投资。他目前在该基金的许多投资组合公司中担任董事，其中包括：Check-Cap Ltd的董事长、Arno Therapeutics的董事。加入Pontifax之前的10年，他在许多技术驱动型企业、初创企业的投资、管理、培育工作中，发挥了重要的作用；还在以色列顶尖的金融机构担任过高级管理职务。他在纽约的Sullivan & Cromwell从事过法律执业；在Harvard University获得经济学士学位，在Harvard Law School获得法律博士学位。
Tomer Kariv is the Chairman of our Board and previously served as a member of the board of directors of Eloxx Pharmaceuticals, Ltd. the “Eloxx Limited Board” since October 2016. For the past 14 years Mr. Kariv has been the Chief Executive Officer and Co-Founder of The Pontifax Group, which established six funds with over $1 billion under management and invested in over 100 portfolio companies. Mr. Kariv also serves on the board of directors of many of The Pontifax Group's portfolio companies including: V-Wave Ltd., EyeYon Medical Ltd., Cathworks Ltd., Raziel Therapeutics Ltd. and Keros Therapeutics, Inc. (a public biotech company where Mr. Kariv serves as chair of the nominating and corporate governance committee). He previously served as a Director of VBI Vaccines Inc., 89Bio Ltd., LogicBio, Entera Ltd., Nutrinia Ltd., Check-Cap Ltd., Headsense Medical Ltd., Macrocure Ltd., Avraham Pharmaceuticals, Stimatix Ltd., Applied Immune Technologies, and Otic Pharma Ltd. Mr. Kariv has 15 years of experience as a seasoned venture capital industry executive and has played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions. Mr. Kariv received a B.A. in Economics from Harvard University and a Juris Doctor from Harvard Law School. - Tomer Kariv，2008年3月加入本公司。他是Pontifax的共同创始人、首席执行官，这是以色列的生命科学行业投资基金集团，也是本公司的股东，专注于发展阶段的生物制药公司、医疗科技公司的投资。他目前在该基金的许多投资组合公司中担任董事，其中包括：Check-Cap Ltd的董事长、Arno Therapeutics的董事。加入Pontifax之前的10年，他在许多技术驱动型企业、初创企业的投资、管理、培育工作中，发挥了重要的作用；还在以色列顶尖的金融机构担任过高级管理职务。他在纽约的Sullivan & Cromwell从事过法律执业；在Harvard University获得经济学士学位，在Harvard Law School获得法律博士学位。
- Tomer Kariv is the Chairman of our Board and previously served as a member of the board of directors of Eloxx Pharmaceuticals, Ltd. the “Eloxx Limited Board” since October 2016. For the past 14 years Mr. Kariv has been the Chief Executive Officer and Co-Founder of The Pontifax Group, which established six funds with over $1 billion under management and invested in over 100 portfolio companies. Mr. Kariv also serves on the board of directors of many of The Pontifax Group's portfolio companies including: V-Wave Ltd., EyeYon Medical Ltd., Cathworks Ltd., Raziel Therapeutics Ltd. and Keros Therapeutics, Inc. (a public biotech company where Mr. Kariv serves as chair of the nominating and corporate governance committee). He previously served as a Director of VBI Vaccines Inc., 89Bio Ltd., LogicBio, Entera Ltd., Nutrinia Ltd., Check-Cap Ltd., Headsense Medical Ltd., Macrocure Ltd., Avraham Pharmaceuticals, Stimatix Ltd., Applied Immune Technologies, and Otic Pharma Ltd. Mr. Kariv has 15 years of experience as a seasoned venture capital industry executive and has played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions. Mr. Kariv received a B.A. in Economics from Harvard University and a Juris Doctor from Harvard Law School.
高管简历
中英对照 | 中文 | 英文- Daniel Geffken
Daniel Geffken自2017年3月起担任CFO。自2011年6月起，他成为Danforth Advisors LLC的联合创始人，并担任董事总经理。Geffken先生还担任Phoenix Biotech Acquisition Corp.、Eloxx Pharmaceuticals，Inc.和OPY Acquisition Corp. I的CFO。Geffken先生曾担任多家上市公司的董事会成员，其中包括Windtree Therapeutics，Inc.，自2019年起担任董事；Arcturus Therapeutics，Inc.，自2017年11月至2018年5月担任董事；Alcobra Pharmaceuticals Inc.，自2013年5月至2017年11月担任董事。Geffken先生自2017年起担任私营公司Elicio Therapeutics的董事会成员。Geffken先生在宾夕法尼亚大学获得经济学学士学位，在哈佛商学院获得工商管理硕士学位。
Daniel Geffken,has served as a member of Windtree Therapeutics, Inc. Board since April 2019 and also serves as Chair of the Audit Committee and as a member of the Compensation Committee. Since 2011, Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Elicio Bio, Alcobra Ltd. and Arcturus Inc., after its merger with Alcobra. Mr. Geffken earned his MBA from Harvard Business School, and his B.S. in Economics from the Wharton School.- Daniel Geffken自2017年3月起担任CFO。自2011年6月起，他成为Danforth Advisors LLC的联合创始人，并担任董事总经理。Geffken先生还担任Phoenix Biotech Acquisition Corp.、Eloxx Pharmaceuticals，Inc.和OPY Acquisition Corp. I的CFO。Geffken先生曾担任多家上市公司的董事会成员，其中包括Windtree Therapeutics，Inc.，自2019年起担任董事；Arcturus Therapeutics，Inc.，自2017年11月至2018年5月担任董事；Alcobra Pharmaceuticals Inc.，自2013年5月至2017年11月担任董事。Geffken先生自2017年起担任私营公司Elicio Therapeutics的董事会成员。Geffken先生在宾夕法尼亚大学获得经济学学士学位，在哈佛商学院获得工商管理硕士学位。
- Daniel Geffken,has served as a member of Windtree Therapeutics, Inc. Board since April 2019 and also serves as Chair of the Audit Committee and as a member of the Compensation Committee. Since 2011, Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Elicio Bio, Alcobra Ltd. and Arcturus Inc., after its merger with Alcobra. Mr. Geffken earned his MBA from Harvard Business School, and his B.S. in Economics from the Wharton School.
- Sumit Aggarwal
Sumit Aggarwal于2021年4月1日加入Eloxx，担任我们的总裁兼首席执行官，自2019年以来一直担任Zikani的总裁兼首席执行官兼董事。Aggarwal先生于2018年加入Zikani，担任首席财务官兼首席商务官，并领导Zikani从一家早期技术公司转变为一家专注于罕见病和肿瘤学的组织。在加入Zikani之前，Aggarwal先生于2015年至2018年担任Progenity, Inc.的代理总裁兼首席财务官，该公司是一家私人基因服务公司，为OB/GYN实践提供产前基因测试。从2016年到2018年，Aggarwal先生担任Neoseq董事会成员，Neoseq是一家私营的基于基因测序的诊断公司。Aggarwal先生还在Adage Capital的医疗保健和生物技术领域担任领导职务，并在McKinsey&Company的医疗保健实践中担任副合伙人。Aggarwal先生在制药和生物技术商业运营，投资管理，管理咨询方面拥有超过20年的经验，并通过重新振兴创新，增长和盈利能力以及为有前途的技术公司筹集资金，成功地改造了公司。Aggarwal先生拥有康奈尔大学约翰逊学院的工商管理硕士学位，以及哈拉格布尔印度理工学院的化学工程学士学位。
Sumit Aggarwal joined Eloxx as our President and Chief Executive Officer on April 1 2021 and previously served as President and Chief Executive Officer and a director of Zikani since 2019. Mr. Aggarwal joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer, and led the transformation of Zikani from an early-stage technology company to a rare disease and oncology-focused organization. Prior to joining Zikani, from 2015 to 2018 Mr. Aggarwal served as acting President and Chief Financial Officer of Progenity, Inc., a private genetic services company offering pre-natal genetic testing to OB/GYN practices. From 2016 to 2018 Mr. Aggarwal served as a member of the board of directors of NEOSEQ, a privately-held genetic sequencing-based diagnostic company. Mr. Aggarwal has also held leadership roles in healthcare and biotechnology at Adage Capital and as an Associate Partner at McKinsey & Company in its healthcare practice. Mr. Aggarwal has more than 20 years of experience in pharmaceutical and biotechnology commercial operations, investment management, management consulting, and has been successful in transforming companies by re-invigorating innovation, growth and profitability, and raising capital for promising technology companies. Mr. Aggarwal holds an M.B.A. with distinction from the Johnson School, Cornell University, and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur.- Sumit Aggarwal于2021年4月1日加入Eloxx，担任我们的总裁兼首席执行官，自2019年以来一直担任Zikani的总裁兼首席执行官兼董事。Aggarwal先生于2018年加入Zikani，担任首席财务官兼首席商务官，并领导Zikani从一家早期技术公司转变为一家专注于罕见病和肿瘤学的组织。在加入Zikani之前，Aggarwal先生于2015年至2018年担任Progenity, Inc.的代理总裁兼首席财务官，该公司是一家私人基因服务公司，为OB/GYN实践提供产前基因测试。从2016年到2018年，Aggarwal先生担任Neoseq董事会成员，Neoseq是一家私营的基于基因测序的诊断公司。Aggarwal先生还在Adage Capital的医疗保健和生物技术领域担任领导职务，并在McKinsey&Company的医疗保健实践中担任副合伙人。Aggarwal先生在制药和生物技术商业运营，投资管理，管理咨询方面拥有超过20年的经验，并通过重新振兴创新，增长和盈利能力以及为有前途的技术公司筹集资金，成功地改造了公司。Aggarwal先生拥有康奈尔大学约翰逊学院的工商管理硕士学位，以及哈拉格布尔印度理工学院的化学工程学士学位。
- Sumit Aggarwal joined Eloxx as our President and Chief Executive Officer on April 1 2021 and previously served as President and Chief Executive Officer and a director of Zikani since 2019. Mr. Aggarwal joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer, and led the transformation of Zikani from an early-stage technology company to a rare disease and oncology-focused organization. Prior to joining Zikani, from 2015 to 2018 Mr. Aggarwal served as acting President and Chief Financial Officer of Progenity, Inc., a private genetic services company offering pre-natal genetic testing to OB/GYN practices. From 2016 to 2018 Mr. Aggarwal served as a member of the board of directors of NEOSEQ, a privately-held genetic sequencing-based diagnostic company. Mr. Aggarwal has also held leadership roles in healthcare and biotechnology at Adage Capital and as an Associate Partner at McKinsey & Company in its healthcare practice. Mr. Aggarwal has more than 20 years of experience in pharmaceutical and biotechnology commercial operations, investment management, management consulting, and has been successful in transforming companies by re-invigorating innovation, growth and profitability, and raising capital for promising technology companies. Mr. Aggarwal holds an M.B.A. with distinction from the Johnson School, Cornell University, and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur.
- Neil S. Belloff
Neil S.Belloff于2020年2月25日成为我们的首席运营官，自2018年6月以来一直担任我们的总法律顾问兼公司秘书。在加入Eloxx之前，Belloff先生自2011年起担任新基医药公司（一家全球生物制药公司）的高级公司法律顾问。Belloff先生还在Deutsche Telekom（世界上最大的电信公司之一）担任了7年的执行副总裁兼美国公司和证券顾问。Belloff先生拥有超过30年的法律和业务经验，在业务关键领域担任重要的管理和项目开发职责，包括风险评估、战略规划、监管合规、并购、资本形成、隐私、制药开发和证券事务。除了公司治理和合规专业知识，Belloff先生还担任华盛顿特区美国证券交易委员会的公司财务部门的高级律师顾问。贝洛夫先生拥有昆尼皮亚克大学法学院的法学博士学位，纽约大学的M.A.，纽约城市大学皇后学院的B.A.学位，并完成了法学硕士的研究生学习。乔治敦大学法律中心证券监管课程。
Neil S. Belloff became our Chief Operating Officer on February 25 2020 and has served as our General Counsel and Corporate Secretary since June 2018. Prior to joining Eloxx, Mr. Belloff was Senior Corporate Counsel at Celgene Corporation, a global biopharmaceutical company, since 2011. Mr. Belloff also served for seven years as Executive Vice President and U.S. Corporate and Securities Counsel at Deutsche Telekom, one of the largest telecommunications companies in the world. Mr. Belloff has more than 30 years of legal and business experience, with significant management and project development responsibilities in business-critical areas including risk assessment, strategic planning, regulatory compliance, mergers and acquisitions, capital formation, privacy, pharmaceutical development, and securities matters. In addition to his corporate governance and compliance expertise, Mr. Belloff served as a Senior Attorney-Advisor in the Division of Corporation Finance at the U.S. Securities and Exchange Commission in Washington, D.C. Mr. Belloff holds a J.D. from Quinnipiac University School of Law, a M.A. from New York University, a B.A. from Queens College of the City University of New York, and completed post-graduate studies in the LL.M. Program in Securities Regulation at Georgetown University Law Center.- Neil S.Belloff于2020年2月25日成为我们的首席运营官，自2018年6月以来一直担任我们的总法律顾问兼公司秘书。在加入Eloxx之前，Belloff先生自2011年起担任新基医药公司（一家全球生物制药公司）的高级公司法律顾问。Belloff先生还在Deutsche Telekom（世界上最大的电信公司之一）担任了7年的执行副总裁兼美国公司和证券顾问。Belloff先生拥有超过30年的法律和业务经验，在业务关键领域担任重要的管理和项目开发职责，包括风险评估、战略规划、监管合规、并购、资本形成、隐私、制药开发和证券事务。除了公司治理和合规专业知识，Belloff先生还担任华盛顿特区美国证券交易委员会的公司财务部门的高级律师顾问。贝洛夫先生拥有昆尼皮亚克大学法学院的法学博士学位，纽约大学的M.A.，纽约城市大学皇后学院的B.A.学位，并完成了法学硕士的研究生学习。乔治敦大学法律中心证券监管课程。
- Neil S. Belloff became our Chief Operating Officer on February 25 2020 and has served as our General Counsel and Corporate Secretary since June 2018. Prior to joining Eloxx, Mr. Belloff was Senior Corporate Counsel at Celgene Corporation, a global biopharmaceutical company, since 2011. Mr. Belloff also served for seven years as Executive Vice President and U.S. Corporate and Securities Counsel at Deutsche Telekom, one of the largest telecommunications companies in the world. Mr. Belloff has more than 30 years of legal and business experience, with significant management and project development responsibilities in business-critical areas including risk assessment, strategic planning, regulatory compliance, mergers and acquisitions, capital formation, privacy, pharmaceutical development, and securities matters. In addition to his corporate governance and compliance expertise, Mr. Belloff served as a Senior Attorney-Advisor in the Division of Corporation Finance at the U.S. Securities and Exchange Commission in Washington, D.C. Mr. Belloff holds a J.D. from Quinnipiac University School of Law, a M.A. from New York University, a B.A. from Queens College of the City University of New York, and completed post-graduate studies in the LL.M. Program in Securities Regulation at Georgetown University Law Center.
- Vijay Modur
Vijay Modur于2021年4月1日成为我们的研究与开发主管，此前曾担任Zikani Therapeutics，Inc.的研发主管，首席科学和医疗官。在担任研发方面的制药和诊断职位的20多年中，Modur博士成功地将研究发现工作转化为影响医疗实践的产品。在加入Zikani之前，Modur博士领导了赛诺菲的文格司他罕见病计划，该计划涵盖了多个罕见病适应症，进入了2期和3期临床开发以及其他早期开发计划。在加入赛诺菲之前，Modur博士在HTG Molecular，Novartis Oncology和Merck Research Labs担任领导职务。Modur博士在卡纳塔克大学获得工商管理硕士学位，在犹他大学获得博士学位。Modur博士是华盛顿大学医学院临床病理学的住院医师，在那里他还完成了博士后奖学金。
Vijay Modur became our Head of Research and Development on April 1 2021 and previously served as the Head of R&D, Chief Scientific and Medical Officer of Zikani Therapeutics, Inc. In his more than 20 years in pharmaceutical and diagnostic roles in R&D, Dr. Modur has successfully translated research discovery efforts into products that impacted medical practice. Prior to joining Zikani, Dr. Modur led the venglustat rare disease program at Sanofi across multiple rare disease indications into phase 2 and phase 3 clinical development as well as other early development programs. Prior to Sanofi, Dr. Modur held leadership roles at HTG Molecular, Novartis Oncology and Merck Research Labs. Dr. Modur obtained his M.B.B.S. from Karnatak University and his Ph.D. from University of Utah. Dr. Modur was a resident in Clinical Pathology at Washington University School of Medicine where he also completed his post-doctoral fellowship.- Vijay Modur于2021年4月1日成为我们的研究与开发主管，此前曾担任Zikani Therapeutics，Inc.的研发主管，首席科学和医疗官。在担任研发方面的制药和诊断职位的20多年中，Modur博士成功地将研究发现工作转化为影响医疗实践的产品。在加入Zikani之前，Modur博士领导了赛诺菲的文格司他罕见病计划，该计划涵盖了多个罕见病适应症，进入了2期和3期临床开发以及其他早期开发计划。在加入赛诺菲之前，Modur博士在HTG Molecular，Novartis Oncology和Merck Research Labs担任领导职务。Modur博士在卡纳塔克大学获得工商管理硕士学位，在犹他大学获得博士学位。Modur博士是华盛顿大学医学院临床病理学的住院医师，在那里他还完成了博士后奖学金。
- Vijay Modur became our Head of Research and Development on April 1 2021 and previously served as the Head of R&D, Chief Scientific and Medical Officer of Zikani Therapeutics, Inc. In his more than 20 years in pharmaceutical and diagnostic roles in R&D, Dr. Modur has successfully translated research discovery efforts into products that impacted medical practice. Prior to joining Zikani, Dr. Modur led the venglustat rare disease program at Sanofi across multiple rare disease indications into phase 2 and phase 3 clinical development as well as other early development programs. Prior to Sanofi, Dr. Modur held leadership roles at HTG Molecular, Novartis Oncology and Merck Research Labs. Dr. Modur obtained his M.B.B.S. from Karnatak University and his Ph.D. from University of Utah. Dr. Modur was a resident in Clinical Pathology at Washington University School of Medicine where he also completed his post-doctoral fellowship.
- Gary D. Rakers
Gary D.Rakers于2020年1月加入Eloxx，此前曾担任我们的公司财务总监兼助理财务主管，并于2021年3月26日晋升为执行董事，财务和会计，公司财务总监兼财务主管。在这之前，Rakers先生在Tesaro, Inc.（一家专注于肿瘤的生物制药公司）工作了6年，最终担任技术会计和运营副总监。Tesaro于2019年被GlaxoSmithKline plc收购。在Totesaro之前，Rakers先生在Deloitte&Touche LLP的审计和保证实践工作了8年，专注于医疗保健和生命科学部门，包括医疗保健提供商，医疗保健保险公司和制药公司，从发现到商业化。Rakers先生是一名注册会计师，拥有本特利大学会计硕士学位。
Gary D. Rakers joined Eloxx in January 2020 previously served as our Corporate Controller and Assistant Treasurer and was promoted to Executive Director, Finance and Accounting, Corporate Controller and Treasurer on March 26 2021. Previously, Mr. Rakers spent 6 years with Tesaro, Inc., an oncology-focused biopharmaceutical company, culminating with the role of Associate Director of Technical Accounting and Operations. Tesaro was acquired by GlaxoSmithKline plc in 2019. Prior toTesaro, Mr. Rakers spent 8 years in the audit and assurance practice of Deloitte & Touche LLP, with a focus on the healthcare and life sciences sector, including healthcare providers, healthcare insurers and pharmaceutical companies from discovery through commercialization. Mr. Rakers, a certified public accountant, holds an M.S.A. in Accounting from Bentley University.- Gary D.Rakers于2020年1月加入Eloxx，此前曾担任我们的公司财务总监兼助理财务主管，并于2021年3月26日晋升为执行董事，财务和会计，公司财务总监兼财务主管。在这之前，Rakers先生在Tesaro, Inc.（一家专注于肿瘤的生物制药公司）工作了6年，最终担任技术会计和运营副总监。Tesaro于2019年被GlaxoSmithKline plc收购。在Totesaro之前，Rakers先生在Deloitte&Touche LLP的审计和保证实践工作了8年，专注于医疗保健和生命科学部门，包括医疗保健提供商，医疗保健保险公司和制药公司，从发现到商业化。Rakers先生是一名注册会计师，拥有本特利大学会计硕士学位。
- Gary D. Rakers joined Eloxx in January 2020 previously served as our Corporate Controller and Assistant Treasurer and was promoted to Executive Director, Finance and Accounting, Corporate Controller and Treasurer on March 26 2021. Previously, Mr. Rakers spent 6 years with Tesaro, Inc., an oncology-focused biopharmaceutical company, culminating with the role of Associate Director of Technical Accounting and Operations. Tesaro was acquired by GlaxoSmithKline plc in 2019. Prior toTesaro, Mr. Rakers spent 8 years in the audit and assurance practice of Deloitte & Touche LLP, with a focus on the healthcare and life sciences sector, including healthcare providers, healthcare insurers and pharmaceutical companies from discovery through commercialization. Mr. Rakers, a certified public accountant, holds an M.S.A. in Accounting from Bentley University.